{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 19bc68b6-83b5-4e33-9b53-caae5e3f66b3 --><h2>Update</h2><!-- end field 19bc68b6-83b5-4e33-9b53-caae5e3f66b3 -->","summary":null,"htmlStringContent":"<!-- begin item fc415a14-eb17-40a0-a8cf-a4a5133d8b86 --><!-- end item fc415a14-eb17-40a0-a8cf-a4a5133d8b86 -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"7d2cb9ad-573c-5de4-9755-7031bbcbead0","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 5b0031f0-01ad-4052-b921-49d0e7d1568e --><h3>New evidence</h3><!-- end field 5b0031f0-01ad-4052-b921-49d0e7d1568e -->","summary":null,"htmlStringContent":"<!-- begin item 39f5f0c8-0c4d-4630-af0a-e0f2eee5e846 --><!-- begin field c42a8385-e0d3-4c10-bd1c-cc5f3270ef7b --><h3>Evidence-based guidelines</h3><!-- end field c42a8385-e0d3-4c10-bd1c-cc5f3270ef7b --><!-- begin field ec4ccc6e-8e9d-4325-8f27-a06ef17c45e2 --><ul><li>Holroyd, C. R., et al. (2018) <em>The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. </em>Oxford Academic. <a data-hyperlink-id=\"0a4e6cac-f8fe-437d-8d07-a95700de367c\" href=\"https://academic.oup.com/journals\">www.academic.oup.com</a> [<a data-hyperlink-id=\"1f82b26c-49ce-4d46-9199-a95700de379a\" href=\"https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/key208/5076446\">Free Full-text</a>]</li><li>EMA (2019) New measures to avoid potentially fatal dosing errors with methotrexate for inflammatory disease. European Medicines Agency. <a href=\"https://www.ema.europa.eu/en\" data-hyperlink-id=\"5705efaf-19e8-45d8-a0a8-aace00ed7d40\">www.ema.europa.eu</a> [<a href=\"https://www.ema.europa.eu/en/news/new-measures-avoid-potentially-fatal-dosing-errors-methotrexate-inflammatory-diseases\" data-hyperlink-id=\"d649ba85-68d0-43f2-b73f-aace00ed7d60\">Free Full-text</a>]</li></ul><!-- end field ec4ccc6e-8e9d-4325-8f27-a06ef17c45e2 --><!-- begin field d8495a03-4b65-4b50-9604-532946dba82b --><h3>HTAs (Health Technology Assessments)</h3><!-- end field d8495a03-4b65-4b50-9604-532946dba82b --><!-- begin field 1ea9c8d5-c7a8-4dd6-8f4c-8a4055a65159 --><p>No new HTA's since 1 October 2017.</p><!-- end field 1ea9c8d5-c7a8-4dd6-8f4c-8a4055a65159 --><!-- begin field ed56fb24-4864-4fb2-a004-5c05dd0f4dd3 --><h3>Economic appraisals</h3><!-- end field ed56fb24-4864-4fb2-a004-5c05dd0f4dd3 --><!-- begin field 22fad510-0624-4b8a-a96f-c6dcce48da6f --><p>No new economic appraisals relevant to England since 1 October 2017.</p><!-- end field 22fad510-0624-4b8a-a96f-c6dcce48da6f --><!-- begin field 8d2189e2-f3c9-42ab-baef-0fb2beb7d67f --><h3>Systematic reviews and meta-analyses</h3><!-- end field 8d2189e2-f3c9-42ab-baef-0fb2beb7d67f --><!-- begin field da78f35e-53fb-4500-82a8-0935024679dd --><p>Veale, D. J., Fearson, U. (2018) The pathogenesis of psoriatic arthritis. The Lancet. <a href=\"https://www.thelancet.com/journals/lancet/issue/current\" data-hyperlink-id=\"8f59d73f-42bb-493b-8cf5-a8fe007f9d5f\">www.thelancet.com</a> [<a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30830-4/fulltext\" data-hyperlink-id=\"2b84fa48-24e0-4bb3-8a87-a8fe007fa38f\">Free Full-text</a>]</p><!-- end field da78f35e-53fb-4500-82a8-0935024679dd --><!-- begin field 2c58d2e3-6eff-4d75-8be4-f2752faf90e3 --><h3>Primary evidence</h3><!-- end field 2c58d2e3-6eff-4d75-8be4-f2752faf90e3 --><!-- begin field ec712de6-a387-4b0d-a786-17210d081a51 --><p>No new controlled trials published in the major journals since 1 October 2017.</p><!-- end field ec712de6-a387-4b0d-a786-17210d081a51 --><!-- end item 39f5f0c8-0c4d-4630-af0a-e0f2eee5e846 -->","subChapters":[]},{"id":"072f52da-3b6e-5939-91c1-e43a64e97e7f","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 6d14540e-f2ef-4d46-89b1-81002a0a500a --><h3>New policies</h3><!-- end field 6d14540e-f2ef-4d46-89b1-81002a0a500a -->","summary":null,"htmlStringContent":"<!-- begin item 911711b5-78c7-483c-a052-651d2cc08c16 --><!-- begin field 5b2c810b-c51e-4375-852a-46a2961437f6 --><p>No new national policies or guidelines since 1 October 2017.</p><!-- end field 5b2c810b-c51e-4375-852a-46a2961437f6 --><!-- end item 911711b5-78c7-483c-a052-651d2cc08c16 -->","subChapters":[]},{"id":"68f7b948-8201-5dc8-aff5-c0ff8d2930c9","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 33e7a55f-1d4b-4e2c-bd02-fd19458969e8 --><h3>New safety alerts</h3><!-- end field 33e7a55f-1d4b-4e2c-bd02-fd19458969e8 -->","summary":null,"htmlStringContent":"<!-- begin item 9ec16b1b-672f-4b5a-bb5d-14a6cf3585ec --><!-- begin field 4064a674-1fa0-4f48-b2b9-1d2a47669e4d --><p>No new safety alerts since 1 October 2017.</p><!-- end field 4064a674-1fa0-4f48-b2b9-1d2a47669e4d --><!-- end item 9ec16b1b-672f-4b5a-bb5d-14a6cf3585ec -->","subChapters":[]},{"id":"34bc1d46-c342-5cfe-95bb-7cea19764845","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field c03ec049-dc38-44d6-a70c-5c2f74195c61 --><h3>Changes in product availability</h3><!-- end field c03ec049-dc38-44d6-a70c-5c2f74195c61 -->","summary":null,"htmlStringContent":"<!-- begin item 59125764-056e-44fc-90fd-a8c066444c27 --><!-- begin field df34d288-2385-4eee-b0dc-b73aa0c80a35 --><ul><li>CHMP has recommended an extension for tofacitinib in combination with MTX for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. See more <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004214/smops/Positive/human_smop_001303.jsp&mid=WC0b01ac058001d127\" data-hyperlink-id=\"0b48eef9-9740-4abe-a54b-a8fe00895a7e\">here</a>. </li><li>European Commission grants marketing authorization for filgotinib for treatment of moderate-to-severe rheumatoid arthritis. Filgotinib is a once-daily, oral, JAK1 inhibitor, recently approved in adults who have responded inadequately to, or who are intolerant to, one or more DMARDs. See more <a href=\"https://www.biospace.com/article/releases/european-commission-grants-marketing-authorization-for-jyseleca-filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis/\" data-hyperlink-id=\"a0272261-a2fb-47ca-91bc-ac4800a653ee\">here</a>.</li></ul><!-- end field df34d288-2385-4eee-b0dc-b73aa0c80a35 --><!-- end item 59125764-056e-44fc-90fd-a8c066444c27 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}